N/A N=100 Technique for Successful Ultrasound-guided Peripheral Vascular Access
Obesity · Vascular Diseases
Primary: Successful First Attempt Peripheral Venous Cannulation — 96 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=252 The Bioseal Vascular Study
Cardiovascular Bleeding · Vascular Bleeding · Hemorrhage
Primary: Hemostasis at the Target Bleeding Site (TBS) at 10 Minutes Following the Completion of Treatment Application. — 96; 88.2 percentage of patients
Phase 3 N=225 Safety and Efficacy Study of Fibrin Sealant Grifols as an Adjunct to Hemostasis During Peripheral Vascular Surgery
Vascular Surgical Bleeding
Primary: Proportion of Subjects Achieving Hemostasis by Four Minutes After Treatment Start — 76.1; 22.8 Percent of subjects achieving hemostasis
N/A N=66 Safety and Accuracy of the Saranas EBBMS for the Detection of Endovascular Procedure Related Bleeding Events
Endovascular Procedures
Primary: Cohen's Kappa Coefficient (κ) — 0.84 proportion of agreement
Phase 4 N=150 EVARREST™ Fibrin Sealant Patch Post-Market Study
Hemorrhage · Soft Tissue Bleeding
Primary: Safety Parameter - Incidence of Thromboembolic Events — 2; 7 Participants
N/A N=52 VASCADE ANTEGRADE-PVD Post-Market Registry
Surgical Wound
Primary: Time to Hemostasis (TTH) — 5.87 minutes
N/A N=204 AMBULATE: Cardiva Mid-Bore VVCS vs. Manual Compression for Multiple Femoral Venous Access Sites, 6 - 12F ID
Surgical Wound
Primary: Time to Ambulation (TTA) — 2.8; 6.1 hours
N/A N=103 SURGICEL® Powder in Controlling Mild or Moderate Parenchymal or Soft Tissue Intraoperative Bleeding in Adult Subjects
Hemorrhage
Primary: Haemostatic Success at 5 Minutes — 90 Participants
N/A N=109 Comparison of Percutaneous Closure to Manual Compression for Hemostasis
Atrial Fibrillation
Primary: Time to Hemostasis — 4.5; 10.7 seconds
N/A N=113 Treatment of Peripheral Arterial Hemorrhage With Lava LES (The LAVA Study)
Peripheral Arterial Hemorrhage
Primary: Percentage of Participants With Composite of Freedom From Major Adverse Events (MAEs) — 100 percentage of participants — p=<0.025
N/A N=75 Caring for the Radial Artery Post-angiogram
Transradial Angiogram
Primary: Bleeding Requiring Intervention After Initial Hemostasis Achieved — 2; 6; 3 participants — p=0.25
Phase 3 N=140 FS VH S/D 500 S-apr in Vascular Surgery
Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethylene (ePTFE) Graft Prostheses
Primary: Percentage of Participants Who Achieved Hemostasis at 4 Minutes Post Treatment Application. — 62.9; 31.4 Percentage of participants — p=<0.0001
N/A N=246 Platelet Activity in Vascular Surgery and Cardiovascular Events
Cardiovascular Disease · Peripheral Artery Disease · Critical Limb Ischemia
Primary: Number of Patients in Which Platelet Activity Measurements Were Associated With Short-term Cardiovascular Events — 31; 16 participants
Phase 3 N=239 Safety and Efficacy Study of Fibrin Sealant Grifols Evaluated as an Adjunct to Hemostasis
Target Bleeding Site During Peripheral Vascular Surgery
Primary: The Primary Efficacy Endpoint is Time to Hemostasis. — 46.4; 26.3; 62.7; 31.6 percentage of subjects
N/A N=90 A Retrospective Study Evaluating the Use of the SoloPath® Sheath in Reducing Vascular and Bleeding Complications
Vascular Access Complication
Primary: Vascular Access Site Complications — 17 participants
N/A N=70 Femoral Vein Hemostasis After Ablation for Atrial Fibrillation With Manual Pressure Versus a Figure of 8 Suture
Atrial Fibrillation
Primary: Time Required to Achieve Hemostasis — 0; 15 minutes
Phase 3 N=721 A Study of Fibrocaps™ in Surgical Bleeding
Mild or Moderate Surgical Bleeding
Primary: Time to Hemostasis (TTH) for Participants Receiving Spinal Surgery — 1.0; 2.5 minutes — p=< 0.0001
N/A N=85 Case Review of the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery
Peripheral Arterial Occlusion or Emboli
Primary: Angiographic Assessment of Vessel Patency at Immediate Post-procedure as Measured by TIMI Scores — 74 Participants
N/A N=171 Multi-center Study for Stent Graft System for Peripheral Artery
Peripheral Arterial Disease
Primary: Primary Assisted Patency — 91 Participants — p=<0.0001
N/A N=30 A Prospective, Multi-Center, Single-Arm Study of the Veriset™ Hemostatic Patch in Controlling Bleeding in Soft Tissue
Non-emergent, Soft Tissue Procedures, Performed Via an Open Approach
Primary: Percent Success in Obtaining Hemostasis Following Veriset Hemostatic Patch Treatment — 29 participants — p=<0.0001
Phase 4 N=148 GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study
Peripheral Vascular Diseases
Primary: Efficacy: Primary Patency at Three Years — 24.2; 25.9 percentage of subjects
Phase 2 N=73 Fibrin Sealant Vascular Surgery Study
Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts)
Primary: Percentage of Participants Achieving Hemostasis at 4 Minutes After Treatment Application at the Study Suture Line. — 46.2; 62.5; 34.8; 30.8 percentage of participants
Phase 3 N=35 The EVARREST® Pediatric Mild or Moderate Liver and Soft Tissue Bleeding Study
Controlling Mild to Moderate Bleeding During Surgery
Primary: Absolute Time to Hemostasis — 4.00 Minutes
N/A N=420 RESPECT Trial - (Rapid Extravascular Sealing Via PercutanEous Collagen ImplanT)
Surgical Wound
Primary: Time to Hemostasis (TTH) — 21.4; 4.8 minutes
Phase 2 N=51 Heart and Hands Study II: A Retrospective Data Collection & Analysis Project
Thrombosis
Primary: Incidence of Arterial Bleeding — 1 Participants
N/A N=106 Suture Closure AFtEr VEIN Access for Cardiac Procedures (SAFE-VEIN) Trial
Atrial Fibrillation · Atrial Flutter · Heart Block
Primary: Time to Achieve Hemostasis — 7; 11 Minutes
N/A N=184 Platelet Inhibition and Bleeding in Patients Undergoing Emergent Cardiac Surgery
Bleeding
Primary: Calculated Blood Loss — 1996 milliters
Phase 3 N=40 The EVARREST® Paediatric Mild/Moderate Liver and Soft Tissue Bleeding Study
Hemorrhage · Soft Tissue Bleeding · Hepatic Parenchyma Bleeding
Primary: Absolute Time to Haemostasis (TTH) — 4.0; 4.0 Minutes
N/A N=168 AMBULATE Continued Access Protocol to Evaluate the Cardiva Mid-Bore Venous Vascular Closure System (VVCS)
Surgical Wound
Primary: Number of Participants With Overall Procedure Success - Effectiveness — 168 Participants
N/A N=90 A Premarket, Prospective, Randomized, Single-Blind Study to Compare the Veriset™ Hemostatic Patch to TachoSil® as an Adjunct to Hemostasis in Subjects Undergoing Cardiovascular Surgery
Cardiac Surgical Procedures · Hemorrhage
Primary: Time to Hemostasis (TTH) — 1.50; 3.00 minutes